Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress

90

DUBLIN–(BUSINESS WIRE)–Horizon Pharma will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for thyroid eye disease. http://www.businesswire.com/news/home/20190412005093/en/Horizon-Pharma-plc-Present-Results-Phase-3/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==